TONELLA, LUCA

TONELLA, LUCA  

SCIENZE MEDICHE  

Mostra records
Risultati 1 - 20 di 22 (tempo di esecuzione: 0.052 secondi).
Titolo Data di pubblicazione Autore(i) File
Acute appendicitis secondary to desmoplastic melanoma metastasis in immune-checkpoint inhibitors era 2021 Avallone, Gianluca; Astrua, Chiara; Fava, Paolo; Tonella, Luca; Mastorino, Luca; Agostini, Andrea; Merli, Martina; Rubatto, Marco; De Pasquale, Rocco; Conti, Luca; Quaglino, Pietro; Ribero, Simone
Alopecia areata after COVID-19 vaccination 2022 Gallo G.; Mastorino L.; Tonella L.; Ribero S.; Quaglino P.
Anti-BRAF/anti-MEK targeted therapies for metastatic melanoma patients during the COVID-19 outbreak: Experience from an Italian skin cancer unit 2021 Quaglino P.; Fava P.; Brizio M.; Marra E.; Rubatto M.; Merli M.; Tonella L.; Ribero S.; Fierro M.T.
CD38 Expression by Circulating and Skin-Infiltrating Lymphocytes from Sezary Syndrome Patients: A Flow Cytometry and Immunohistochemistry Study 2022 Quaglino P.; Novelli M.; Fava P.; Ortolan E.; Astrua C.; Tonella L.; Tomasini C.F.; Senetta R.; Ribero S.; Ponti R.; Fierro M.T.; Funaro A.
Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer 2022 Rubatto, Marco; Sciamarrelli, Nadia; Borriello, Silvia; Pala, Valentina; Mastorino, Luca; Tonella, Luca; Ribero, Simone; Quaglino, Pietro
Clinical evaluation of hydration index using a corneometer in metastatic melanoma patients treated with BRAF/MEK inhibitors: a prospective study 2022 Amabile, Simone; Tonella, Luca; Rubatto, Marco; Argenziano, Giuseppe; Babino, Graziella; Frascione, Pasquale; Dika, Emi; Giacomelli, Luca; Parodi, Aurora; Quaglino, Pietro
Clinical significance of distant metastasis-free survival (Dmfs) in melanoma: A narrative review from adjuvant clinical trials 2021 Amabile S.; Roccuzzo G.; Pala V.; Tonella L.; Rubatto M.; Merli M.; Fava P.; Ribero S.; Fierro M.T.; Queirolo P.; Quaglino P.
Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study 2022 Gullo G.; Rubatto M.; Fava P.; Brizio M.; Tonella L.; Ribero S.; Medri M.; Avallone G.; Mastorino L.; Fierro M.T.; Stanganelli I.; Quaglino P.
Differences in cutaneous melanoma survival between the 7th and 8th edition of the American Joint Committee on Cancer (AJCC). A multicentric population-based study 2021 Barreiro-Capurro A.; Andres-Lencina J.J.; Podlipnik S.; Carrera C.; Requena C.; Manrique-Silva E.; Quaglino P.; Tonella L.; Jaka A.; Richarz N.; Rodriguez-Peralto J.L.; Ortiz P.; Boada A.; Ribero S.; Nagore E.; Malvehy J.; Puig S.
Effectiveness and Safety of Dupilumab for the Treatment of Atopic Dermatitis in Adult Cohort: a Real-Life Italian Tertiary Centre Experience 2020 Ribero S, Giura MT, Viola R, Ramondetta A, Siliquini N, Cardone P, Tonella L, Quaglino P, Dapavo P, Panzone M, Ortoncelli M, Fierro MT.
Emerging prognostic biomarkers in advanced cutaneous melanoma: a literature update 2024 Roccuzzo, Gabriele; Bongiovanni, Eleonora; Tonella, Luca; Pala, Valentina; Marchisio, Sara; Ricci, Alessia; Senetta, Rebecca; Bertero, Luca; Ribero, Simone; Berrino, Enrico; Marchiò, Caterina; Sapino, Anna; Quaglino, Pietro; Cassoni, Paola
Evolution of different clinical patterns of cutaneous lesions in a suspected COVID-19 patient 2020 Quaglino P.; Fava P.; Cariti C.; Ortoncelli M.; Aimetti M.; Milan A.; Dapavo P.; Tonella L.; Ribero S.; Fierro M.T.
Exploring the role of epigenetic alterations and non-coding RNAs in melanoma pathogenesis and therapeutic strategies 2023 Rubatto Marco; Borriello Silvia; Sciamarrelli Nadia; Pala Valentina; Tonella Luca; Ribero Simone; Quaglino Pietro
Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives 2021 Roccuzzo G.; Giordano S.; Fava P.; Pileri A.; Guglielmo A.; Tonella L.; Sanlorenzo M.; Ribero S.; Fierro M.T.; Quaglino P.
Infections in Sézary syndrome: A retrospective cohort study of 113 patients 2022 Cariti C.; Quaglino P.; Lupia T.; Novelli M.; Marra E.; Fava P.; Caliendo V.; Tonella L.; De Rosa F.G.; Fierro M.T.; Ribero S.
Metastatic melanoma treatment with checkpoint inhibitors in the COVID-19 era: experience from an Italian Skin Cancer Unit 2020 Quaglino P.; Fava P.; Brizio M.; Marra E.; Rubatto M.; Agostini A.; Tonella L.; Ribero S.; Fierro M.T.
Nutritional interventions for patients with melanoma: From prevention to therapy—an update 2021 Pellegrini M.; D'eusebio C.; Ponzo V.; Tonella L.; Finocchiaro C.; Fierro M.T.; Quaglino P.; Bo S.
Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and/or Sézary Syndrome 2021 Quaglino P.; Fava P.; Pileri A.; Grandi V.; Sanlorenzo M.; Panasiti V.; Guglielmo A.; Alberti-Violetti S.; Novelli M.; Astrua C.; Rubatto M.; Tonella L.; Berti E.; Pimpinelli N.; Osella Abate S.; Fierro M.T.; Vermeer M.; Scarisbrick J.J.; Ribero S.
Predictive value of baseline [18f]fdg pet/ct for response to systemic therapy in patients with advanced melanoma 2021 Liberini V.; Rubatto M.; Mimmo R.; Passera R.; Ceci F.; Fava P.; Tonella L.; Polverari G.; Lesca A.; Bello M.; Arena V.; Ribero S.; Quaglino P.; Deandreis D.
Prognostic and predictive biomarkers in stage iii melanoma: Current insights and clinical implications 2021 Tonella L.; Pala V.; Ponti R.; Rubatto M.; Gallo G.; Mastorino L.; Avallone G.; Merli M.; Agostini A.; Fava P.; Bertero L.; Senetta R.; Osella-Abate S.; Ribero S.; Fierro M.T.; Quaglino P.